It suggests a luteolytic effect of the GnRH antagonist that lead to a decrease of ovarian activity and angiogenic factors secretion, resulting in regression of severe OHSS (4, 8). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.